Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.
Department of Cardiology, St. Carollo Hospital, Republic of Korea.
Catheter Cardiovasc Interv. 2019 Sep 1;94(3):378-384. doi: 10.1002/ccd.28032. Epub 2019 Jan 2.
We aimed to investigate specific subgroups in which the benefit of transradial coronary interventions (TRIs) would be enhanced.
The advantage of TRIs over transfemoral coronary interventions (TFIs) might differ according to a given clinical condition, urgency of the procedure, and operator volume pattern.
Using a cohort from the 2014 Korean Percutaneous Coronary Intervention Registry, in-hospital outcomes of the TRI group (n = 22,993) were matched to those of the TFI group (n = 15,581). After propensity score matching, the composite endpoints between the groups and subgroups for all-cause death, nonfatal myocardial infarctions (MIs), or transfusions were analyzed.
The composite endpoints occurred less frequently in the TRI group than the TFI group [2.1% vs. 5.5%, OR 0.63, 95% CI 0.55-0.72]. The TRI group had a lower rate of death (OR 0.44, 95% CI 0.33-0.60) and nonfatal MI (OR 0.66, 95% CI 0.54-0.81) than the TFI group. The TRI group required fewer transfusions than the TFI group (OR 0.72, 95% CI 0.59-0.88). TRI benefits were consistent across subgroups except patients with chronic kidney disease and those treated in low tertile PCI volume centers. The favorable outcome of TRI was greater in the elderly (≥75 years), patients with ST-elevation MI, those who underwent emergent PCI, and those treated in high tertile PCI volume hospitals (P for the interaction <0.001 for all).
Compared to TFI, TRI had favorable composite in-hospital outcomes. TRI benefits were pronounced in high-risk clinical settings and in high PCI volume centers.
我们旨在研究能够增强经桡动脉冠状动脉介入治疗(TRI)获益的特定亚组。
TRI 相较于经股动脉冠状动脉介入治疗(TFI)的优势可能因特定临床情况、手术紧迫性和术者操作量模式而有所不同。
利用 2014 年韩国经皮冠状动脉介入治疗注册研究的队列,将 TRI 组(n=22993)的住院期间结局与 TFI 组(n=15581)进行匹配。在进行倾向评分匹配后,分析两组及各亚组的全因死亡、非致死性心肌梗死(MI)或输血复合终点。
TRI 组的复合终点发生率低于 TFI 组[2.1%比 5.5%,比值比 0.63,95%置信区间 0.55-0.72]。TRI 组的死亡率(比值比 0.44,95%置信区间 0.33-0.60)和非致死性 MI(比值比 0.66,95%置信区间 0.54-0.81)发生率均低于 TFI 组。TRI 组的输血需求低于 TFI 组(比值比 0.72,95%置信区间 0.59-0.88)。除慢性肾脏病患者和低 PCI 量中心治疗的患者外,TRI 的获益在各亚组中均一致。TRI 的良好结局在高龄(≥75 岁)、ST 段抬高型心肌梗死患者、紧急 PCI 患者和高 PCI 量中心治疗的患者中更为显著(所有 P 交互<0.001)。
与 TFI 相比,TRI 具有更有利的住院期间复合结局。TRI 的获益在高危临床情况下和高 PCI 量中心更为显著。